Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a common and aggressive form of leukemia, yet current treatment strategies remain insufficient. Venetoclax, a BH3-mimetic approved for AML treatment, induces Bcl-2-dependent apoptosis, though its therapeutic efficacy is still limited. Therefore, new strategies to enhance the effect of venetoclax are highly sought. Valproic acid (VPA), commonly used for epilepsy, has also been studied for potential applications in AML treatment.

Methods

AML cells were treated with venetoclax, with or without VPA. Cell viability was assessed using the trypan blue dye exclusion assay, while cell cycle progression was analyzed by flow cytometry. The expression of pro-apoptotic proteins Bax and Bak was measured by RT-qPCR.

Results

Venetoclax and V

SUBMITTER: Kawakatsu R 

PROVIDER: S-EPMC11764158 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature